Log in to search using one of your social media accounts:

 

' You Don't Always Need to Do More': De-escalating Breast Cancer Therapy'You Don't Always Need to Do More': De-escalating Breast Cancer Therapy

Patients diagnosed with breast cancer could soon be benefiting from what could be described as the next step in personalized therapy: de-escalation of treatment to minimize adverse effects.Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Article Source Type: news

Related Links:

Publication date: Available online 20 May 2018 Source:The Journal of Steroid Biochemistry and Molecular Biology Author(s): Cristina Amaral, Tiago Vieira Augusto, Elisiário Tavares-da-Silva, Fernanda M.F. Roleira, Georgina Correia-da-Silva, Natércia Teixeira The leading cause of cancer death in women around the world is breast cancer. The aromatase inhibitors (AIs) are considered a first-line treatment for estrogen receptor-positive (ER+) breast tumors, in postmenopausal women. Exemestane (Exe) is a powerful steroidal AI, however, despite its therapeutic success, Exe-acquired resistance may occur leading to t...
Source: The Journal of Steroid Biochemistry and Molecular Biology - Category: Biochemistry Source Type: research
Publication date: 1 August 2018 Source:Life Sciences, Volume 206 Author(s): Qian Zhou, Chaoqun You, Cong Zheng, Yawen Gu, Hongchao Gu, Rui Zhang, Hongshuai Wu, Baiwang Sun DNA is considered to be one of the most promising targets for anticancer agents. Acridine analogues have anticancer activity based on DNA binding and topoisomerases inhibition. However, due to the side effects, resistance and low bioavailability, a few have entered into clinical usage and the mechanisms of action are not fully understood. Novel acridine derivatives are needed for effective cancer therapy. A series of novel 3-nitroacridine-based derivati...
Source: Life Sciences - Category: Biology Source Type: research
Authors: Aqbi HF, Tyutyunyk-Massey L, Keim RC, Butler SE, Thekkudan T, Joshi S, Smith TM, Bandyopadhyay D, Idowu MO, Bear HD, Payne KK, Gewirtz DA, Manjili MH Abstract Breast cancer patients who initially respond to cancer therapies often succumb to distant recurrence of the disease. It is not clear why people with the same type of breast cancer respond to treatments differently; some escape from dormancy and relapse earlier than others. In addition, some tumor clones respond to immunotherapy while others do not. We investigated how autophagy plays a role in accelerating or delaying recurrence of neu-overexpressing...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Jafarirad S, Hammami Torghabe E, Rasta SH, Salehi R Abstract In the present research, an effective drug-free approach was developed to kill MCF7 breast cancer cells using low-level laser therapy (LLLT) combined with reduced graphene oxide (rGO)-based hybrid nanocomposites (NCs). Here, fruit extract of Rosa canina was used for the first time to obtain the rGO/ZnO, Ag-ZnO/rGO and Nd-ZnO/rGO NCs by green synthesis. Physico/photochemical properties of these NCs were evaluated using FTIR, XRD, Raman, XPS, SEM/EDX, UV-Vis, DLS and AFM. The potential of the as-synthesized NCs on ROS generating and antioxidant act...
Source: Artificial Cells, Nanomedicine and Biotechnology - Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research
Abstract Rising evidence has shown the development of resistance to vascular endothelial growth factor receptor (VEGFR) inhibitors in the practices of cancer therapy. It is reported that the efficacy of axitinib (AX), a VEGFR inhibitor, is limited in the treatment of breast cancer as a single agent or in combination with other chemotherapeutic drugs due to the probability of rising population of cancer stem-like cells (CSCs) caused by AX. The present study evaluated the effect of dopamine (DA) improving AX's efficacy on MCF-7/ADR breast cancer in vitro and in vivo, and developed a pharmacokinetic-pharmacodynamic (...
Source: Acta Pharmacologica Sinica - Category: Drugs & Pharmacology Authors: Tags: Acta Pharmacol Sin Source Type: research
Publication date: 30 July 2018 Source:International Journal of Pharmaceutics, Volume 546, Issues 1–2 Author(s): Tao Zhang, Meng Li, Ruyi Yang, Dong Zhang, Jibin Guan, Jiang Yu, Bin Yang, Huicong Zhang, Shenwu Zhang, Dan Liu, Yongjun Wang Docetaxel (DTX) solution is among the most widely-used parenteral formulations used in advanced breast cancer therapy. However, severe side effects have been observed due to the use of ethanol and polysorbate 80. Herein, a novel DTX-based prodrug, docetaxel-linoleic acid conjugate (DTX-LA) was successfully synthesized. The high lipid solubility of DTX and DTX-LA resulted in a tenden...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
This study aimed to evaluate the clinical and prognostic value of MCTs used by immunohistochemistry and quantum dots-based fluorescent imaging technique in BC and surrounding stroma with emphasis on the interaction between tumour and stroma. Moreover, the data from The Cancer Genome Atlas (TCGA) was analyzed to evaluate the association between MCTs mRNA expression and prognosis of breast cancer patients. Our study found that MCT1 overexpression was observed in hormone receptor-negative and high-proliferation subtypes. High expression of MCT1 and MCT4 in tumour tissues was associated with poor patient outcome; further the c...
Source: Biochemical and Biophysical Research communications - Category: Biochemistry Authors: Tags: Biochem Biophys Res Commun Source Type: research
Identification of a Wells-Dawson polyoxometalate-based AP-2γ inhibitor with pro-apoptotic activity. Biochem J. 2018 May 14;: Authors: Hu J, Tan SK, Lim MGL, Chang SH, Cui G, Liu S, Narasimhan K, New SY, Wang X, Chen C, Chakravarty H, Kolatkar PR, Tam KY, Lu Q, Su X, Jauch R, Cheung E Abstract AP-2 gamma (AP-2γ) is a transcription factor that plays pivotal roles in breast cancer biology. To search for small molecule inhibitors of AP-2γ, we performed a high-throughput fluorescence anisotropy screen and identified a polyoxometalate compound with Wells-Dawson structure K6[P2Mo18O62] (Daw...
Source: The Biochemical Journal - Category: Biochemistry Authors: Tags: Biochem J Source Type: research
Publication date: Available online 3 May 2018 Source:Nanomedicine: Nanotechnology, Biology and Medicine Author(s): Alevtina S. Semkina, Maxim A. Abakumov, Alexander S. Skorikov, Tatiana O. Abakumova, Pavel A. Melnikov, Nadejda F. Grinenko, Sergey A. Cherepanov, Daniil A. Vishnevskiy, Victor A. Naumenko, Klavdiya P. Ionova, Alexander G. Majouga, Vladimir P. Chekhonin In presented paper we have developed new system for cancer theranostics based on vascular endothelial growth factor (VEGF) targeted magnetic nanoparticles. Conjugation of anti-VEGF antibodies with bovine serum albumin coated PEGylated magnetic nanoparticles al...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research
Publication date: Available online 21 April 2018 Source:Nanomedicine: Nanotechnology, Biology and Medicine Author(s): Varun Kushwah, Sameer S. Katiyar, Ashish Kumar Agrawal, Ramesh C. Gupta, Sanyog Jain The present report deals with conjugation of dual drug; docetaxel (DTX) and gemcitabine (GEM) with linker poly-ethylene-glycol (PEG) to develop amphiphilic molecule having self-assembled property. The synthesized conjugate (DTX-PEG-GEM) demonstrated critical micelle concentration (CMC) in the range of 5–10 μg/ml which self-assembled to form NPs with size 124.2 ± 5.7. Remarkably higher coumarin-6 (C-6) f...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Health | Hematology